Foreword

We are delighted to present the 2022 / 23 Annual Report of the EuroQol Research Foundation.

The EuroQol Research Foundation is a not-for-profit organisation that aims to improve decisions about health and health care throughout the world by developing, promoting and supporting the use of instruments with the widest possible applicability for the measurement and valuation of health. As this report demonstrates, its work is worldwide in focus and reach, which enables evidence on health outcomes to be given a central role in healthcare decisions.

EQ-5D instruments are among the most widely used and recommended tools worldwide for measuring population and patient health. The instruments – and the preference weights that accompany them – have played a pivotal role in the establishment of health technology assessment (HTA) systems around the world and are mandated or recommended in several key countries for use in HTA. The instruments are increasingly also used in population health surveys, and in routine outcomes measurement in healthcare systems. This helps to ensure health care is effective and cost effective, and that resources are used to achieve improvements in health and reductions in health inequalities.

When looking at all EQ-5D deliveries via the EuroQol Customer Portal, the vast majority of these are for non-commercial users of EuroQol instruments who can use EQ-5D completely free of charge. This includes healthcare systems, government bodies and academic researchers. Revenue from sponsorship and license fees paid by commercial users (primarily the life sciences industry) helps to promote scientific research that directly contributes to developing and supporting use of our instruments to improve healthcare decision-making. All users are supported by our dedicated office team, who facilitate access to the thousands of versions of our instruments that now exist across multiple languages, formats and modes of administration.
The Foundation’s substantial and sustained investment in research ensures that we continually strengthen and expand our family of measurement tools. This commitment to R&D marks EuroQol out from other instrument developers. It has also led to EuroQol being firmly established as the leading innovator in methods used to generate preference weights for health-related quality of life (HRQoL).

This report provides an overview of EuroQol’s research programme and describes how we support and promote the measurement of health worldwide.

The accomplishments outlined in this report have resulted from the efforts of a strong and committed network of researchers – members of the EuroQol Group, formally constituted as the EuroQol Group Association. Their work is supported by an exceptionally strong scientific team based in Rotterdam, who play a pivotal role in the direction and management of the overall programme of scientific research.

This report outlines an impressive record of achievement over the past year, and we thank all our members and the EuroQol staff who have contributed to it.

Nancy Devlin  
Chair of the Board  
EuroQol Research Foundation

Rosalie Viney  
Chair of the Executive Committee  
EuroQol Group Association
Introduction to EuroQol
Introduction to EuroQol

Based in the Netherlands, the EuroQol Research Foundation is a Dutch not-for-profit foundation (ANBI) that aims to improve decisions about health and health care throughout the world by developing, promoting and supporting the use of instruments. The Foundation manages the worldwide distribution and licensing of EuroQol instruments. The EuroQol Group, which develops those instruments, is an international member-based organisation connecting multidisciplinary researchers active in the field of measurement and valuation of health.

Globally, the EQ-5D is one of the most widely used concise, generic measures of HRQoL. Most requests to use it result in free-of-charge use; a license fee is only charged for commercial use (<20% of users). As the primary source of income for the Foundation, licensing has become an internationally important source of research funding that has helped to develop the EuroQol Group into a thriving network of scientists advancing the field of health measurement and valuation.

With over 25 professionals across various disciplines, the Foundation’s office team handles requests for the use of EuroQol instruments, manages the maintenance and development of EuroQol instruments and their many translations, and oversees the research funding programme. The team works within the governance structures of the EuroQol Group and its members, to ensure that the EuroQol Foundation makes the best use of available funds.

Globally, EuroQol has 120 members who support the Foundation to reach its goals. There are six Working Groups (WGs), each charged with clearly defined, specific objectives relating to the scientific agenda of the EuroQol Group. To support users and advance research, there are further groups such as the Version Management Committee (VMC), overseeing translations and version maintenance; and the Industry Consultation Group (ICG), which consults industry as a key customer of EuroQol instruments.
Our organisational structure

- **EuroQol Group Association**
  - 120 members worldwide
- **EuroQol Research Foundation**
  - Registered charity
- **Board**
  - Principal governance committee of the Foundation, 5 members
- **The EuroQol Office**
  - Rotterdam
- **Scientific support**
- **Legal / Office support**
- **Member administration**
- **Version management**
- **EQ-5D support**
- **Communications**
- **Industry Consultation Group**

**Sections**
- Introduction to EuroQol
- Main achievements
  - Development and distribution of EuroQol instruments
  - Grant funding activities
  - Dissemination and knowledge transfer
- Financial report
- Acknowledgements
Our vision and mission statement

OUR VISION
To improve decisions about health and health care throughout the world by developing, promoting and supporting the use of instruments with the widest possible applicability for the measurement and valuation of health.

OUR MISSION
• To provide leadership in the research and development of instruments that describe and value health.
• To promote the use of instruments developed by the EuroQol Group and to support individuals and organisations across the world seeking to use those instruments.
• To foster and support an international community of researchers whose activity informs the development and application of EuroQol Group instruments.
• To ensure access to the accumulated research expertise of the EuroQol Group and to actively promote the transfer of knowledge and evidence regarding the use, analysis, and interpretation of measures developed by the EuroQol Group.
• To support promising early career researchers in the field of health and quality of life research through involvement in EuroQol Group activities.
EuroQol as an instrument development organisation

All EQ-SD instruments comprise a short questionnaire (the ‘EQ-5D descriptive system’), and a visual analogue scale (‘EQ VAS’). The responses on the descriptive system can be summarised using value sets, which reflect views of the general population (usually a specific country or region) about the value of each health state.

EuroQol is currently working on ensuring that the whole lifespan of a person can be covered with different questionnaires within the EQ-5D family. The current family of instruments includes the original three-level version (EQ-5D-3L), the expanded five-level version (EQ-5D-5L) and a three-level version suitable for use in children (EQ-5D-Y-3L). The five-level child-friendly version (EQ-5D-Y-5L) is expected to become available in 2024.

*IA, interviewer administered; Proxy, completed by caregiver.

<table>
<thead>
<tr>
<th>Age Group</th>
<th>EQ-TIPS (Proxy)</th>
<th>Modified Version</th>
<th>Youth Version</th>
<th>Youth Version</th>
<th>Adult Version</th>
<th>Adult Version</th>
</tr>
</thead>
<tbody>
<tr>
<td>0–3 years</td>
<td>EQ-5D-Y-3L Proxy</td>
<td>EQ-5D-Y-3L Proxy/IA*</td>
<td>EQ-5D-Y-3L Proxy/IA*</td>
<td>EQ-5D-Y-3L</td>
<td>EQ-5D-3L</td>
<td>EQ-5D-3L</td>
</tr>
<tr>
<td>2–4 years</td>
<td>EQ-5D-Y-3L Proxy</td>
<td>EQ-5D-Y-3L Proxy/IA*</td>
<td>EQ-5D-Y-3L Proxy/IA*</td>
<td>EQ-5D-Y-5L</td>
<td>EQ-SD-5L</td>
<td>EQ-SD-5L</td>
</tr>
<tr>
<td>8–12 years</td>
<td>EQ-5D-Y-3L Proxy</td>
<td>EQ-5D-Y-3L Proxy/IA*</td>
<td>EQ-5D-Y-3L Proxy/IA*</td>
<td>EQ-5D-Y-5L</td>
<td>EQ-SD-5L</td>
<td>EQ-SD-5L</td>
</tr>
<tr>
<td>12–15 years</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16–17 years</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥18 years</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Expanding the family of EQ-5D instruments to cover an individual’s entire lifespan requires accurate ways of measuring and valuing HRQoL at both ends of the age spectrum. Two new experimental instruments are in development for early childhood:

- **EQ-TIPS (EQ-Toddler and Infant Populations)**
  Designed for ages 0–3 years, EQ-TIPS is currently being globally tested by collaborators. Based on the EuroQol model, it includes extra/different dimensions relevant for this youngest age group.

- **Modified EQ-5D-Y-3L and EQ-5D-Y-5L adapted for 2–4-year olds**
  For children aged 2–4 years and currently being tested by collaborators. The existing EQ-5D dimensions are retained, but the wording has been amended.

We have also developed the 25-item EQ Health and Wellbeing instrument (EQ-HWB) and a classifier to generate preference weights, the 9-item EQ-HWB-S. The measures assess quality of life relating to health, informal care, and social care associated with aspects of health and social care most frequently used by the elderly, those with chronic conditions, and informal carers. To define and manage research priorities for both instruments, the EQ-HWB Working Group was established in March 2023. Ongoing R&D collaborations are collecting psychometric evidence that will help refine the two instruments, as well as informing further research. Methods to develop preference-weighted value sets for the EQ-HWB-S are currently being explored.
Main achievements
Main achievements

EuroQol in numbers | Financial year 2022/23

- 6091 completed EQ-5D requests
- 241 funded research projects
- 75 newly funded this year
- 82% free of charge
- 18% paid EQ-5D deliveries
- Total income: €11,377,998
- 93% of income spent on achieving mission objectives
- *7% is used for overhead costs
- Development and distribution of EuroQol instruments
Completed requests for using EQ-5D instruments

EuroQol’s primary source of income is license fees. EQ-5D instruments are usually provided free of charge for academic, public health and other non-commercial projects, large or small. The instruments can generally be obtained quickly, without any license agreement.

Commercial users (e.g. pharmaceutical company, medical device manufacturer, or any other for-profit stakeholder) must pay a license fee.

In FY 2022/23, EuroQol granted 6091 requests for the EQ-5D – using over 200 different language versions, in 125 countries around the world. Of these, 82% of deliveries were free of charge. Note that this does not mean that 18% of EQ-5D users are commercial companies, as commercial users are allowed to start any number of studies for 3 years under the same license. For every new study, a new delivery is made in the Portal. This means that the actual percentage of commercial users is much lower than 18%.
Use of the EQ-5D instruments: Key highlights

Use of EQ-5D in COVID-19 studies
Since the start of the COVID pandemic, EuroQol has offered study-specific licenses free of charge to commercial customers who use the EQ-5D instruments in clinical trials aimed at testing COVID-19 treatments or diagnostic tools. Today, around 50 research papers using the EQ-5D to measure the impact on COVID-19 on HRQoL are available on PubMed. Recently, major population health studies like the Population Health Impact of the COVID-19 Pandemic (POPCORN) study (Principal Investigator [PI]: Juanita Haagsma) and the COVID-19 Vaccine Preference and Opinion Survey (CANDOUR) (PIs: Philip Clarke and Mara Violato), financially supported by EuroQol, published their results showing the population health impact of the COVID-19 pandemic measured by the EQ-SD.1-3

Use of EQ-5D in value-based health care
Besides using EQ-5D to calculate quality-adjusted life-years (QALYs) to inform health economic evaluations, EQ-5D instruments are increasingly used as patient-reported outcome measures (PROMs). This shift towards a patient-centred approach has had a significant impact on the measurement and valuation of health: the patient identifies relevant PROMs/PREMs (patient-reported experience measures), while routine outcomes monitoring (ROM) signals how closely healthcare delivery aligns with these outcomes and experiences. EuroQol also invested in a seed grant testing how EQ-5D could become part of clinical dashboards, aiding data-driven clinical decisions.

Key customer service improvements

We are implementing several initiatives to further improve responsiveness to our customers.

UPGRADING CUSTOMER SUPPORT SERVICE

A single form was developed to channel all support requests regarding EQ-5D registration, licensing, translations, recommended use, scoring, data analysis, reporting, valuation, etc. This reduced our turnaround time for providing customer support to ≤2 business days.

CUSTOMER SUPPORT TEAM

The EuroQol Office team is currently reorganised to establish a customer-facing dedicated support team. This streamlines the processing of customer requests, enabling a more rapid response.

REGISTRATION PROCESS FOR USING EUROQOL INSTRUMENTS

We are updating the process for obtaining our instruments, to make all stages of the registration process more user-friendly and transparent.
One aspect of our work: Legal support

The legal team

In each annual report, we describe some of the Foundation's day-to-day operations. Every year a lot of legal work is done behind the scenes - from drafting and updating various types of user agreement, to implementing new internal policies. The legal team manages and monitors these activities.

The legal team's focus was on a smooth registration process and timely product delivery to customers in the FY 2022/23. Their responsibilities include:

• Overseeing and processing requests for EuroQol products, including legal agreements for their use in registered studies
• Facilitating collaboration requests for experimental versions
• Ensuring trademark registrations for all instruments (including experimental and modified versions)

• Securing IP rights for all instruments – this controls quality by ensuring that clients always work with the correct versions and encourages innovation by protecting new materials from unauthorised changes
• Internal legal matters such as drafting and maintaining cyber-security policy and privacy statements, or ensuring the Foundation’s compliance with data protection requirements such as GDPR.

In FY 2022/23, the legal team managed 6091 completed requests for using EQ-5D instruments. Their attention was directed towards updating and developing agreements to align with new policies, speeding up the application process, and facilitating customer access to the requested versions (e.g. introducing automated terms of use for non-commercial customers). Moving forward, the team aims to further prioritise customer-centric approaches and shorten timelines.
- Grant funding activities
Our research grants

- We funded **75 new research projects** in 2022-2023. The average grant size was €64,000.
- We launched the **Research Seed Grants in 2022** to support innovative research and funded projects by distributing a total grant size of €150,000 in FY 2022/23. This aims to encourage interest among external research groups to develop new collaborations with the EuroQol Group in research projects where EQ-5D or EQ-5D data play a key role.
- Grants were provided to research projects **worldwide**: Asia, Africa, North America, South America, Europe, and Oceania.
- We have funded several projects in some African countries as part of our **focus on stimulating research in low- or middle-income countries (LMIC)**, such as:
  - **Egypt**: A validation study comparing the measurement properties of EQ-5D-Y-3L and EQ-5D-Y-5L (PI: Samar Farid).
  - **Africa**: The large-scale Population Quality of Life (POPQOL) study, which aims to assess the population’s HRQoL and investigate health inequalities within and across different African countries (PI: Begashaw Melaku Gebresillassie).
  - **South Africa**: We funded a pre-congress session on EQ-5D as a measure of population health at the International Health Economics Association (IHEA) conference in Cape Town, July 2023, to promote large-scale health system research for the family of EuroQol instruments in Africa. EuroQol also funded travel grants for several early career researchers from LMIC to attend IHEA.
Special focus on youth

As in the previous year, major research efforts were focused on the measurement and valuation of youth health.

Various studies explored the measurement properties of EQ-5D-Y-5L in comparison to EQ-5D-Y-3L in different populations and countries – such as the Quality of Life in Kids: Key Evidence to Strengthen Decisions in Australia (QUOKKA) research programme (funded by Australian Government Medical Research Future Fund grant #1200816 and by EuroQol; PI: Nancy Devlin). The Younger Populations WG is working hard to prepare for the launch of the EQ-5D-Y-5L.

The large-scale EQ-TIPS project (PI: Janine Verstraete) looks at measuring health in the youngest population, children aged 0–3 years. Through a series of online surveys and forum/discussion groups with various stakeholders, information was gathered to clarify the needs of potential users of the instrument, and their views on the EQ-TIPS and the data it produces. This information helps to evaluate the content, acceptability and appropriateness of the EQ-TIPS descriptive system.

Five new EQ-5D-Y-3L value sets (for Belgium, China, Hungary, Indonesia and the Netherlands) were published. Additional valuation studies for the EQ-5D-Y-3L are still underway, including in the UK and the USA.

Preliminary explorative work on the EQ-5D-Y-5L valuation has been undertaken. A multi-country pilot study has explored the labels of the EQ-5D-Y-5L and its valuation by adults and adolescents (PI: Nancy Devlin).

EuroQol members are also active in youth healthcare evaluation outside the EuroQol Group, e.g. in the ISPOR Task Force Valuing HRQoL of Children & Adolescents in Economic Evaluation (Pediatric Utilities) with six EuroQol member representatives (chairs: Nancy Devlin and Donna Rowen).
- Dissemination and knowledge transfer
How we increased our impact: Dissemination and knowledge transfer

Meetings
We hosted three in-person events to disseminate new research findings and provide networking and educational opportunities. Fully funded travel and accommodation were made available where needed.

• The EuroQol Plenary Meeting in Chicago, USA in September 2022 hosted 114 participants and 33 online attendees. In total, there were 28 paper and 21 poster presentations. A workshop on advanced psychometric methods was organised by the Descriptive Systems WG alongside the Plenary Meeting.

• The theme at the EuroQol Academy Meeting in March 2023 in Milan/Italy was: ‘From cradle to grave: Can we measure and value HRQoL consistently over the lifespan?’ This theme emphasised the focus of EuroQol developing EQ-5D instruments to cover an individual’s entire life. The event saw 123 in-person and 37 online attendees participating in educational sessions and 14 poster presentations. The same topic was chosen for a symposium that we hosted at ISPOR Europe 2022 (Vienna, Austria).

• The first EuroQol Latin America Academy Meeting was held in Trinidad and Tobago in November 2022, in collaboration between the EuroQol Group and the University of the West Indies. Altogether, 56 delegates from 17 countries – including EuroQol members, academics and government representatives – participated in the educational sessions and 14 poster presentations.
Webinars
We have hosted five webinars that have helped us increase our reach and audience. These include ‘EQ-5D-Y for Children with Intellectual Disability’ and ‘APERSU – The Story of Applying the EQ-5D as a PROM in Alberta, Canada’ (see past and scheduled webinars).

Grants for education and outreach
In FY 2022/23, EuroQol funded 10 travel/visiting and knowledge transfer grants, totalling €130,740. This included sessions at conferences, workshops in a clinical setting, and individual travel grants for conferences or research visits, such as:

- IHEA pre-congress session ‘EQ-5D as a Measure of Population Health’ (South Africa, July 2023)
- Workshop for using the EQ-5D as a PROM for improving clinical and shared decision-making in routine care (Singapore, May 2023).

Research data management
The EuroQol Group continuously supports researchers in their scientific activities by updating its professional services, facilities and operational procedures to align with the evolving technical, legal and scientific requirements for managing research data. The SAVED (Storage and Access for Valuable EuroQol Datasets) initiative continued in FY 2022/23 by establishing infrastructure and workflow, incorporating SAVED into all proposal requests. The first dataset transfers are underway to make data available for secondary use and ensuring compliance with ‘FAIR’ (findable, accessible, interoperable, reusable) data principles.
Early career research support

The EuroQol Group aims to foster an international community of researchers by providing opportunities for involvement, research, and networking. Based on its stringent membership criteria, EuroQol offers a valuable forum for well-established researchers. We also help to foster new generations of young researchers who will help to shape the future of science.

Created in 2022, the EuroQol PhD Network (Chairs: Benjamin Craig and Joshua Bonsel) builds a supportive environment for doctoral students involved in EuroQol research. From the initial cohort of 21 founding members in 2022, the PhD Network doubled in size by May 2023 (to 41 doctoral students), including members from Oceania, Europe, North America, South America and Asia.

In FY 2022/23, the Network has held two receptions (at the EuroQol Plenary Meeting and Academy Meeting), four student research webinars, and three online educational panels. In the panels, EuroQol members shared their specialist expertise with Network members and other early career researchers, with topics such as ‘Lessons from Industry’, ‘A Brief History of the EuroQol Group’ and ‘How the EuroQol Office Can Help You’ (see the list of meetings on the EuroQol website).

EuroQol has expanded opportunities for early career researchers by continuing the PhD funding programme with three new grants and one budget extension to develop a project into PhD research. We now support 12 PhD students worldwide (Oceania, Europe, North America, Africa and Asia). EuroQol also arranged the 3rd Early Career Researchers Meeting (Milan, March 2023), which hosted 36 attendees to view 10 paper and 12 poster presentations of early career researchers.
Showcase

New resources and educational materials have been made available free of charge to users of the family of EQ-5D instruments to support processing and interpretation of EQ-5D data. In the context of our open access publishing policy, EuroQol funded 35 open access fees totalling €100,000 to enable wider sharing of all EuroQol-funded research reporting.

- A themed section in *PharmacoEconomics* contains a collection of papers reporting methodological and conceptual issues of the valuation of the EQ-5D-Y-3L, as well as six EQ-5D-Y-3L value sets.

- EuroQol published an introductory slide set on the EQ VAS, to accompany the whiteboard animation.
Financial report
Our financial year

In FY 2022/23, invoiced income decreased by 6.3%. Taking deferred income into consideration, total sponsorship revenue increased by 3.7%, from €10,974,645 in FY 2021/22 to €11,377,998 in FY 2022/23.

Due to an overall increase of costs for the organisation, particularly scientific meeting costs, the Foundation was able to approve research projects for a lower total value compared with the previous year, amounting to €5,290,508. This is a decrease of 3% compared with FY 2021/22.

The total value of research expenses to be paid increased from €11,497,765 in FY 2021/22 to €11,794,852 in FY 2022/23. This includes €7,006,756 for projects that started over a year ago. Commitments to fund research expenses currently extend as far as 2027.
# Balance sheet as of 30 June 2023

(after appropriation of the result)

<table>
<thead>
<tr>
<th>ASSETS</th>
<th>30 June 2023</th>
<th>30 June 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Fixed assets</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intangible fixed assets</td>
<td>82,312</td>
<td>123,468</td>
</tr>
<tr>
<td>Tangible fixed assets</td>
<td>164,170</td>
<td>195,220</td>
</tr>
<tr>
<td><strong>Current assets</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Receivables and prepayments</td>
<td>4,361,899</td>
<td>3,117,333</td>
</tr>
<tr>
<td>Taxes and social securities</td>
<td>393,544</td>
<td>119,176</td>
</tr>
<tr>
<td>Stocks and bonds</td>
<td>25,144,540</td>
<td>23,874,019</td>
</tr>
<tr>
<td>Cash at bank</td>
<td>2,433,190</td>
<td>3,724,326</td>
</tr>
<tr>
<td></td>
<td>32,333,173</td>
<td>30,834,854</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>32,579,655</td>
<td>31,153,542</td>
</tr>
</tbody>
</table>
EQUITY AND LIABILITIES

<table>
<thead>
<tr>
<th></th>
<th>30 June 2023</th>
<th>30 June 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Reserves</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Continuity reserve</td>
<td>1,427,208</td>
<td>1,522,657</td>
</tr>
<tr>
<td>Reserves allocated to research areas</td>
<td>1,132,000</td>
<td>1,132,000</td>
</tr>
<tr>
<td>Total reserves</td>
<td>2,559,208</td>
<td>2,654,657</td>
</tr>
<tr>
<td><strong>Non-current liabilities (longer than 1 year)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre-invoiced sponsorship</td>
<td>7,520,252</td>
<td>6,962,328</td>
</tr>
<tr>
<td>Research expenses to be paid</td>
<td>7,006,756</td>
<td>7,358,301</td>
</tr>
<tr>
<td></td>
<td>14,527,008</td>
<td>14,320,629</td>
</tr>
<tr>
<td><strong>Current liabilities, accruals and deferred income (within 1 year)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre-invoiced sponsorship</td>
<td>9,700,838</td>
<td>8,999,056</td>
</tr>
<tr>
<td>Creditors</td>
<td>425,408</td>
<td>567,348</td>
</tr>
<tr>
<td>Taxes and social securities</td>
<td>–</td>
<td>41,922</td>
</tr>
<tr>
<td>Research expenses to be paid</td>
<td>4,788,096</td>
<td>4,139,464</td>
</tr>
<tr>
<td>Other current liabilities and accruals</td>
<td>579,097</td>
<td>430,466</td>
</tr>
<tr>
<td></td>
<td>15,493,439</td>
<td>14,178,256</td>
</tr>
<tr>
<td></td>
<td><strong>32,579,655</strong></td>
<td><strong>31,153,542</strong></td>
</tr>
</tbody>
</table>
Statement of income and expenditure for the year ended 30 June 2023

<table>
<thead>
<tr>
<th></th>
<th>2022 / 2023</th>
<th>2021 / 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Income</strong></td>
<td>€</td>
<td>€</td>
</tr>
<tr>
<td>Sponsorship</td>
<td>11,377,998</td>
<td>10,974,645</td>
</tr>
<tr>
<td><strong>Expenditure</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spent on research and education</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Approved projects</td>
<td>5,290,508</td>
<td>5,451,793</td>
</tr>
<tr>
<td>Support on approved projects</td>
<td>1,006,272</td>
<td>667,150</td>
</tr>
<tr>
<td>Other core expenditures</td>
<td>3,508,586</td>
<td>1,920,044</td>
</tr>
<tr>
<td></td>
<td>-9,805,366</td>
<td>-8,038,987</td>
</tr>
<tr>
<td>Management and administration</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Personnel costs</td>
<td>1,558,830</td>
<td>1,230,099</td>
</tr>
<tr>
<td>Depreciation tangible fixed assets</td>
<td>44,117</td>
<td>29,630</td>
</tr>
<tr>
<td>Depreciation intangible fixed assets</td>
<td>41,156</td>
<td>41,156</td>
</tr>
<tr>
<td>General expenses</td>
<td>526,613</td>
<td>491,152</td>
</tr>
<tr>
<td></td>
<td>-2,170,716</td>
<td>-1,792,037</td>
</tr>
<tr>
<td>Operating result</td>
<td>-598,084</td>
<td>1,143,621</td>
</tr>
<tr>
<td>Financial results</td>
<td>502,635</td>
<td>-968,079</td>
</tr>
<tr>
<td><strong>Result</strong></td>
<td><strong>-95,449</strong></td>
<td><strong>175,542</strong></td>
</tr>
</tbody>
</table>
Spending on mission objectives

I To provide leadership in the research and development of instruments that describe and value health. (61%)

II To promote the use of instruments developed by the EuroQol Group and to support individuals and organisations across the world seeking to use those instruments. (19%)

III To foster and support an international community of researchers whose activity informs the development and applications of EuroQol Group instruments. (4%)

IV To ensure access to the accumulated research expertise of the EuroQol Group and to actively promote the transfer of knowledge and evidence regarding the use, analysis, and interpretation of measures developed by the EuroQol Group. (12%)

V To support promising early career researchers in the field of health and quality of life research through involvement in EuroQol Group activities. (4%)

93% of our spending is in line with our Vision and Mission.
Acknowledgements
Who supported our mission?

We are grateful to all our supporters over the years. In particular, we thank members of the EuroQol Group Association for their tireless support of the Foundation’s activities. Today the EuroQol Group has 120 members, from 30 countries, who offer a diverse range of experience and skills. In countries like the Netherlands, there are founding EuroQol members and multiple generations of research members. Many have served the Foundation by taking up positions in EuroQol bodies, such as the Executive Committee, Board, VMC, ICG, or scientific WGs.
Glossary

**ANBI**  *Algemeen nut beogende instelling*  
[Public benefit organisation]

**CANDOUR**  COVID-19 Vaccine Preference and Opinion Survey

**FAIR**  Findable, accessible, interoperable, reusable  
[data principles]

**GDPR**  General Data Protection Regulation

**HRQoL**  Health-related quality of life

**HTA**  Health technology assessment

**IA**  Interviewer administered

**ICG**  Industry Consultation Group

**IHEA**  International Health Economics Association

**ISPOR**  Professional Society for Health Economics and Outcomes Research

**LMIC**  Low- or middle-income countries

**PI**  Principal Investigator

**POPCORN**  Population Health Impact of the COVID-19 Pandemic  
[study]

**POPQOL**  Population Quality of Life  
[study]

**PREMs**  Patient-reported experience measures

**PROMs**  Patient-reported outcome measures

**QALYs**  Quality-adjusted life-years

**QUOKKA**  Quality of Life in Kids: Key Evidence to Strengthen Decisions in Australia  
[study]

**R&D**  Research and development

**ROM**  Routine outcomes monitoring

**SAVED**  Storage and Access for Valuable EuroQol Datasets

**VAS**  Visual analogue scale

**VMC**  Version Management Committee

**WG**  Working Group

This annual report was developed by the EuroQol Communications Team, led by Kristina Ludwig  
EuroQol Research Foundation

www.euroqol.org